ADAM9 is a novel product of polymorphonuclear neutrophils: Regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury

Robin Roychaudhuri, Anja H. Hergrueter, Francesca Polverino, Maria E. Laucho-Contreras, Kushagra Gupta, Niels Borregaard, Caroline A. Owen

Research output: Contribution to journalArticle

Abstract

A disintegrin and a metalloproteinase domain (ADAM) 9 is known to be expressed by monocytes and macrophages. In this study, we report that ADAM9 is also a product of human and murine polymorphonuclear neutrophils (PMNs). ADAM9 is not synthesized de novo by circulating PMNs. Rather, ADAM9 protein is stored in the gelatinase and specific granules and the secretory vesicles of human PMNs. Unstimulated PMNs express minimal quantities of surface ADAM9, but activation of PMNs with degranulating agonists rapidly (within 15 min) increases PMN surface ADAM9 levels. Human PMNs produce small quantities of soluble forms of ADAM9. Surprisingly, ADAM9 degrades several extracellular matrix (ECM) proteins, including fibronectin, entactin, laminin, and insoluble elastin, as potently as matrix metalloproteinase-9. However, ADAM9 does not degrade types I, III, or IV collagen or denatured collagens in vitro. To determine whether Adam9 regulates PMN recruitment or ECM protein turnover during inflammatory responses, we compared wild-type and Adam9-/-mice in bacterial LPS-and bleomycin-mediated acute lung injury (ALI). Adam9 lung levels increase 10-fold during LPS-mediated ALI in wild-type mice (due to increases in leukocyte-derived Adam9), but Adam9 does not regulate lung PMN (or macrophage) counts during ALI. Adam9 increases mortality, promotes lung injury, reduces lung compliance, and increases degradation of lung elastin during LPS-and/or bleomycin-mediated ALI. Adam9 does not regulate collagen accumulation in the bleomycin-treated lung. Thus, ADAM9 is expressed in an inducible fashion on PMN surfaces where it degrades some ECM proteins, and it promotes alveolar-capillary barrier injury during ALI in mice. Copyright

Original languageEnglish (US)
Pages (from-to)2469-2482
Number of pages14
JournalJournal of Immunology
Volume193
Issue number5
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Acute Lung Injury
Extracellular Matrix Proteins
Proteolysis
Neutrophils
Lung
Elastin
Bleomycin
Collagen
Macrophages
Disintegrins
Lung Compliance
Gelatinases
Neutrophil Activation
Collagen Type III
Collagen Type IV
Neutrophil Infiltration
Matrix Metalloproteinase 9
Secretory Vesicles
Lung Injury
Metalloproteases

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

ADAM9 is a novel product of polymorphonuclear neutrophils : Regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury. / Roychaudhuri, Robin; Hergrueter, Anja H.; Polverino, Francesca; Laucho-Contreras, Maria E.; Gupta, Kushagra; Borregaard, Niels; Owen, Caroline A.

In: Journal of Immunology, Vol. 193, No. 5, 01.09.2014, p. 2469-2482.

Research output: Contribution to journalArticle

Roychaudhuri, Robin ; Hergrueter, Anja H. ; Polverino, Francesca ; Laucho-Contreras, Maria E. ; Gupta, Kushagra ; Borregaard, Niels ; Owen, Caroline A. / ADAM9 is a novel product of polymorphonuclear neutrophils : Regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury. In: Journal of Immunology. 2014 ; Vol. 193, No. 5. pp. 2469-2482.
@article{c3e38e6b227a4dc39db171a044ffe1f3,
title = "ADAM9 is a novel product of polymorphonuclear neutrophils: Regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury",
abstract = "A disintegrin and a metalloproteinase domain (ADAM) 9 is known to be expressed by monocytes and macrophages. In this study, we report that ADAM9 is also a product of human and murine polymorphonuclear neutrophils (PMNs). ADAM9 is not synthesized de novo by circulating PMNs. Rather, ADAM9 protein is stored in the gelatinase and specific granules and the secretory vesicles of human PMNs. Unstimulated PMNs express minimal quantities of surface ADAM9, but activation of PMNs with degranulating agonists rapidly (within 15 min) increases PMN surface ADAM9 levels. Human PMNs produce small quantities of soluble forms of ADAM9. Surprisingly, ADAM9 degrades several extracellular matrix (ECM) proteins, including fibronectin, entactin, laminin, and insoluble elastin, as potently as matrix metalloproteinase-9. However, ADAM9 does not degrade types I, III, or IV collagen or denatured collagens in vitro. To determine whether Adam9 regulates PMN recruitment or ECM protein turnover during inflammatory responses, we compared wild-type and Adam9-/-mice in bacterial LPS-and bleomycin-mediated acute lung injury (ALI). Adam9 lung levels increase 10-fold during LPS-mediated ALI in wild-type mice (due to increases in leukocyte-derived Adam9), but Adam9 does not regulate lung PMN (or macrophage) counts during ALI. Adam9 increases mortality, promotes lung injury, reduces lung compliance, and increases degradation of lung elastin during LPS-and/or bleomycin-mediated ALI. Adam9 does not regulate collagen accumulation in the bleomycin-treated lung. Thus, ADAM9 is expressed in an inducible fashion on PMN surfaces where it degrades some ECM proteins, and it promotes alveolar-capillary barrier injury during ALI in mice. Copyright",
author = "Robin Roychaudhuri and Hergrueter, {Anja H.} and Francesca Polverino and Laucho-Contreras, {Maria E.} and Kushagra Gupta and Niels Borregaard and Owen, {Caroline A.}",
year = "2014",
month = "9",
day = "1",
doi = "10.4049/jimmunol.1303370",
language = "English (US)",
volume = "193",
pages = "2469--2482",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - ADAM9 is a novel product of polymorphonuclear neutrophils

T2 - Regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury

AU - Roychaudhuri, Robin

AU - Hergrueter, Anja H.

AU - Polverino, Francesca

AU - Laucho-Contreras, Maria E.

AU - Gupta, Kushagra

AU - Borregaard, Niels

AU - Owen, Caroline A.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - A disintegrin and a metalloproteinase domain (ADAM) 9 is known to be expressed by monocytes and macrophages. In this study, we report that ADAM9 is also a product of human and murine polymorphonuclear neutrophils (PMNs). ADAM9 is not synthesized de novo by circulating PMNs. Rather, ADAM9 protein is stored in the gelatinase and specific granules and the secretory vesicles of human PMNs. Unstimulated PMNs express minimal quantities of surface ADAM9, but activation of PMNs with degranulating agonists rapidly (within 15 min) increases PMN surface ADAM9 levels. Human PMNs produce small quantities of soluble forms of ADAM9. Surprisingly, ADAM9 degrades several extracellular matrix (ECM) proteins, including fibronectin, entactin, laminin, and insoluble elastin, as potently as matrix metalloproteinase-9. However, ADAM9 does not degrade types I, III, or IV collagen or denatured collagens in vitro. To determine whether Adam9 regulates PMN recruitment or ECM protein turnover during inflammatory responses, we compared wild-type and Adam9-/-mice in bacterial LPS-and bleomycin-mediated acute lung injury (ALI). Adam9 lung levels increase 10-fold during LPS-mediated ALI in wild-type mice (due to increases in leukocyte-derived Adam9), but Adam9 does not regulate lung PMN (or macrophage) counts during ALI. Adam9 increases mortality, promotes lung injury, reduces lung compliance, and increases degradation of lung elastin during LPS-and/or bleomycin-mediated ALI. Adam9 does not regulate collagen accumulation in the bleomycin-treated lung. Thus, ADAM9 is expressed in an inducible fashion on PMN surfaces where it degrades some ECM proteins, and it promotes alveolar-capillary barrier injury during ALI in mice. Copyright

AB - A disintegrin and a metalloproteinase domain (ADAM) 9 is known to be expressed by monocytes and macrophages. In this study, we report that ADAM9 is also a product of human and murine polymorphonuclear neutrophils (PMNs). ADAM9 is not synthesized de novo by circulating PMNs. Rather, ADAM9 protein is stored in the gelatinase and specific granules and the secretory vesicles of human PMNs. Unstimulated PMNs express minimal quantities of surface ADAM9, but activation of PMNs with degranulating agonists rapidly (within 15 min) increases PMN surface ADAM9 levels. Human PMNs produce small quantities of soluble forms of ADAM9. Surprisingly, ADAM9 degrades several extracellular matrix (ECM) proteins, including fibronectin, entactin, laminin, and insoluble elastin, as potently as matrix metalloproteinase-9. However, ADAM9 does not degrade types I, III, or IV collagen or denatured collagens in vitro. To determine whether Adam9 regulates PMN recruitment or ECM protein turnover during inflammatory responses, we compared wild-type and Adam9-/-mice in bacterial LPS-and bleomycin-mediated acute lung injury (ALI). Adam9 lung levels increase 10-fold during LPS-mediated ALI in wild-type mice (due to increases in leukocyte-derived Adam9), but Adam9 does not regulate lung PMN (or macrophage) counts during ALI. Adam9 increases mortality, promotes lung injury, reduces lung compliance, and increases degradation of lung elastin during LPS-and/or bleomycin-mediated ALI. Adam9 does not regulate collagen accumulation in the bleomycin-treated lung. Thus, ADAM9 is expressed in an inducible fashion on PMN surfaces where it degrades some ECM proteins, and it promotes alveolar-capillary barrier injury during ALI in mice. Copyright

UR - http://www.scopus.com/inward/record.url?scp=84907029438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907029438&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1303370

DO - 10.4049/jimmunol.1303370

M3 - Article

C2 - 25063875

AN - SCOPUS:84907029438

VL - 193

SP - 2469

EP - 2482

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -